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INTRODUCTION
Hepatitis C virus (HCV) is a major cause of posttransfusion hepatitis and chronic liver disease [1, 2] . More than half of patients with acute HCV infections develop chronic hepatitis that leads to liver cirrhosis and/or hepatocellular carcinoma in at least 20% of cases [3, 4] . Treatment of HCV with interferon (IFN)-α and ribavirin is associated with a sustained response rate of nearly 40% [5, 6] , which is likely to improve to 55% of treated patients with the use of pegylated IFN-α and ribavirin in [7, 8] .
Helicobacter pylori (H.pylori) is a gram-negative bacillus that colonizes the mucous layer of the human stomach. This bacterium has been causally linked with a diverse spectrum of gastrointestinal disorders, including gastritis, peptic ulcer disease, gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma.
Several studies have reported association of H.pylori infection to a variety of liver diseases, such as hepatitis A virus, primary biliary cirrhosis, and autoimmune hepatitis [9] [10] [11] [12] [13] [14] [15] [16] [17] . Patients with chronic liver diseases have also been reported to be significantly more likely to be infected with H.pylori than controls. Pellicano et al. reported that approximately 90% of 254 patients with HCV-related cirrhosis in Italy were seropositive for anti-H.pylori antibodies [11] . However, there is no current evidence as to whether H.pylori worsens the course of coexistent hepatitis C. In addition, the effect of H.pylori on HCV response to IFN-α and ribavirin is largely unknown.
The objective of this study was to determine the prevalence of anti-H.pylori seropositivity in Japanese patients with chronic hepatitis C, the influence of anti-H. pylori seropositivity on the clinical, virological, and histological characteristics of hepatitis C, and the effect of H.pylori coinfection on HCV response to IFN-α and ribavirin therapy.
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PATIENTS AND METHODS

Patients
IFN and ribavirin combination therapy
IFN-α 2b (Schering-Plough, Tokyo, Japan) was administered at a dosage of 6 million units (MU) daily for 2 weeks, followed by 6 MU three times a week for 22 weeks (total dose, 480 million U). Rivabirin was taken daily for 24 weeks (body weight <60 kg, 600 mg/day; ≥60 kg, 800 mg/day). Patients were followed for at least 6 months after therapy. For all patients, serum samples were obtained prior to therapy and stored at -70°C until testing. Additional serum samples were collected just before therapy began, during therapy, immediately after therapy was completed, and 6 months post-therapy.
Serum ALT levels were measured prior to therapy and, in patients receiving IFN-α and ribavirin therapy, at least once every 4 weeks both during therapy and follow-up. Sustained virological responders (SVRs) to IFN and rivabirin therapy were defined as those whose HCV RNA in serum was undetectable 24 weeks after completing therapy. Non-responders and relapsers who did not meet SVR criteria were defined as non-SVRs.
Necroinflammatory activity was scored according to the histology activity index (HAI) by Knodell et al [18] . The HAI score was determined by combining the scores for portal inflammation (0-4), lobular degeneration and necrosis (0-4), and periportal necrosis (0-10). Fibrosis stage was defined according to the Scheuer fibrosis score: 0, absence; 1, fibrous portal expansion; 2, periportal or portoportal fibrosis; 3, bridging fibrosis; 4, cirrhosis [19] . Investigators involved in this part of the study were blinded to the results of other portions.
Safety was assessed in this study by recording adverse events reported by patients, clinical laboratory test results (including hematology, blood chemistry, and urinalysis), and vital signs.
Serological markers and molecular assays for HCV, HBV, HIV and H. pylori
Anti-HCV antibody, hepatitis B surface antigen and antibody to human immunodeficiency virus were measured using commercially available enzyme-linked immunosorbent assays (International Reagents Co., Kobe, Japan). IgG class antibody to H.pylori (anti-H.pylori) was also detected using an enzyme immunoassay kit (Kyowa Medex Co., Tokyo, Japan). This particular assay has been shown to be an accurate and reliable method for detection of H. pylori infection, and is based on high-molecular-weight cell-associated antigens which are highly conserved complexes with important conformational determinants. The enzyme immunoassay kit cutoffs used were those recommended by the manufacturer and were as follows: positive, >2.2 enzyme immunoassay value (EV); indeterminate, 1.8-2.2 EV; and negative, <1.8 EV [20] . In this study, patients positive for anti-H.pylori were defined as > 2.2 EV in serum. Patients who did not meet these criteria, including negative and indeterminate, were regarded as negative for anti-H.pylori. The sensitivity and specificity of this assay were 94.0% and 82.4%, respectively. Serum levels of HCV RNA were determined using qualitative and quantitative COBAS AMPLICOR assays (Nippon Roche Co. Ltd, Tokyo, Japan), which amplify HCV RNA by reverse-transcription-polymerase chain reaction [21] . HCV genotypes were determined by INNO-LiPA HCV II (Innogenetics, Gent, Belgium). ALT, and other relevant biochemical tests, were performed using standard methods.
Statistical analysis
Mann-Whitney U test was used to analyze continuous variables. Chi-square test with
Yates' correction was used for the analysis of categorical data. Pearson's correlation coefficient was used to evaluate the relationships between the titer of anti-H.pylori and platelet count or fibrosis score. Multivariate analysis was performed using a logistic regression model with a stepwise method. A p value of ≤ 0.05 was considered Umemura H.pylori and chronic hepatitis C 6 significant. Statistical analyses were performed using SigmaStat (version 2.03, SPSS Inc., Chicago, IL) and SPSS 6.1J (SPSS Inc., Chicago, IL).
RESULTS
Detection of H.pylori
Anti-H.pylori antibody was detected in 45 of 93 (48%) patients. The median serum anti-H.pylori and HCV RNA levels were 1.7 EV (range, 0.4-7.0) and 686 KIU/ml (range, 6.1-850), respectively. Clinical and virologic features were compared between patients with and without anti-H.pylori in Table 1 (Figure 1 ).
The rate of HCV response to IFN-α and ribavirin therapy did not differ between patients with and without anti-H.pylori (Table 1) .
Effect of H.pylori infection on HCV response to IFN-α and ribavirin therapy
Of the 93 patients receiving IFN-α and ribavirin therapy, 42 (45%) were SVRs. There was no significant difference between SVRs and non-SVRs according to sex, history of blood transfusion, or median ALT level at the onset of therapy. SVRs were found more frequently in younger patients (P=0.032) ( 
DISCUSSION
In this study, we found that approximately 50% of Japanese patients with chronic hepatitis C were coinfected with H.pylori. This anti-H.pylori seroprevalence is similar to our recent report on healthy individuals in Japan [10] . Although the urea breath test is more specific for an active H.pylori detection, the treatment arm of this study was designed to measure HCV response to IFN-α and ribavirin therapy. Further study using the urea breath test is needed to clarify the exact frequency of H.pylori in chronic patients.
Concerning disease severity, it has been reported that dual infection with HCV and either hepatitis A virus or hepatitis B virus was associated with more severe and rapidly progressive liver disease [22] [23] [24] . However, no evidence was found to would be required to validate this result. While HCV genotype and pre-treatment HCV RNA level were seen to be significantly associated with HCV treatment response in this and prior studies [32, 33] , there was no significant difference in the sustained HCV treatment response between those who had HCV infection alone and those with HCV and H.pylori coinfection.
Over the past few years, Helicobacter species have been found to be present in the liver of HCV negative patients, and have been associated with hepatocellular carcinoma (HCC) development in the non-cirrhotic liver [14, 34, 35] . Rocha et al. [16] have recently reported that virtually all patients with HCC are Helicobacter species Recently, H.pylori has been suspected to be involved in various autoimmune disorders, including idiopathic thrombocytopenia [36, 37] . Several studies have also reported that the eradication of H.pylori is often accompanied by a significant increase in platelet count in patients with idiopathic thrombocytopenia [37, 38] . (Table 4) , fibrosis score and the presence of H.pylori were significantly associated with a decrease in platelet count during IFN and ribavirin therapy. Hence, it might be useful to eradicate H.pylori prior to therapy, which would presumably increase platelet count and decrease the rate of reduction or cessation of IFN. Since the treatment arm of the study was initially designed to measure HCV response only, eradication of H.pylori had not been performed.
Eradication of H.pylori in patients with chronic hepatitis C prior to IFN and ribavirin therapy is currently being planned in a forthcoming study. 
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